Apomorphine and certain ergot alkaloids (bromocriptine, lisuride and pergolide) have been
available for several decades; for the last few years, they were joined by newer dopamine …

Levodopa combined with a peripheral dopa-decarboxylase inhibitor (DCI) has been
considered the therapy of choice for Parkinson's disease (PD). Levodopa is nearly always …

Dopamine receptor agonists are pharmacological agents with diverse physical and
chemical properties that share the capacity to stimulate dopamine receptors and provide an …

Oral levodopa is the most effective symptomatic treatment for Parkinson's disease.
Dopamine agonists are useful adjuvants to levodopa in the pharmacotherapy of …

The occurrence of late side effects of long term levodopa therapy (fluctuations in motor
performance, abnormal movements, and symptoms unresponsive to …

Three new dopamine agonists (cabergoline, pramipexole, ropinirole) have been put on to
the market within the past months to treat patients with Parkinson's disease. Like any …

With the intention of compensating for the deficit of endogenous dopamine (DA) in the basal
ganglia of Parkinsonian patients by substitution with agents which directly stimulate central …

Publisher Summary Dopamine agonists are useful medications for the management of
patients with Parkinson's disease (PD) in the early stages as well as in more advanced …

Dopamine agonists are effective in the management of both advanced and early-stage
Parkinson's disease. Unfortunately, randomized head-to-head comparative studies between …

Opinion statement Although dopamine receptor agonists are not simple to use, they are
assuming increased importance in the treatment of early and advanced symptoms of …